Delcath Systems, Inc. DCTH

DCTH Company Overview

Delcath Systems, Inc. is a U.S.-based interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. The company develops and commercializes targeted regional therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure. Delcath operates primarily within the oncology medical device and specialty pharmaceutical sectors, with its commercial and clinical efforts centered on hepatic-directed cancer therapies.

The company’s principal product platform is the HEPZATO KIT, a combination drug-device product used in hepatic delivery of melphalan through a proprietary percutaneous hepatic perfusion (PHP) system. Revenue generation is primarily tied to commercialization of the therapy in the United States and related clinical adoption activities. Delcath has historically focused on metastatic uveal melanoma and other unresectable hepatic-dominant malignancies. The company was founded in 1988 and evolved from a development-stage medical technology company into a commercial-stage oncology company following U.S. regulatory approvals and expanded commercialization efforts.